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Abstract: 
 
The principal stimulus that evokes pulmonary hypertension is chronic alveolar hypoxia. 
Pulmonary hypertension is associated with remodeling of the vessel walls, involving hypertrophy 
and hyperplasia of pulmonary arterial smooth muscle (PASM) and a concomitant increase in the 
deposition of connective tissue, resulting in increased wall thickness. The purpose of the present 
study was to determine the effect of hypoxia-induced hypertension on the structure and function 
of PASM. Experiments were designed to determine whether hypoxia-induced pulmonary 
hypertension is associated with alterations in PASM: 1) reactivity to a variety of agonists, 2) 
contractile protein proportions and isoforms, and 3) structural properties. Young adult male rats 
were made hypoxic by lowering the fraction of inspired O2 (10%) for 14 days. Pulmonary 
arterial segments were isolated and dose-response curves to various agonists (high K+, 
norepinephrine, serotonin, angiotensin II, and adenosine) were generated. Gel electrophoresis 
was used to measure changes in the relative amounts of actin or myosin and of myosin heavy 
chain (MHC) isoforms. Structural changes were correlated with the pharmacological and 
biochemical data. Hypoxia-induced pulmonary hypertension caused a general decreased 
reactivity, an increase in the proportion of nonmuscle to muscle MHC isoforms in PASM, and an 
increase in arterial wall thickness with PASM hypertrophy or hyperplasia. 
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Article: 
 
Pulmonary hypertension is a primary event leading to the development of right ventricular 
failure and respiratory failure. The principal stimulus that evokes pulmonary hypertension is 
chronic alveolar hypoxia. Local alveolar hypoxia causes an acute vasoconstriction and increased 
arterial resistance. When the hypoxia affects the whole lung rather than discrete regions and is 
chronic rather than acute, pulmonary hypertension results. Remodeling of the vessel walls, 
including an increase in wall thickness by hypertrophy and hyperplasia of the pulmonary arterial 
smooth muscle (PASM) and an increase in the deposition of connective tissue, accompanies 
hypoxia-induced pulmonary hypertension (3, 21, 24, 30). Whether the vascular wall remodeling 
precedes or occurs concomitantly with the pulmonary hypertension has not been established. 
Reid (24) has suggested that although vasoconstriction plays a role in some types of 
hypertension, ultimately, the structural changes and not smooth muscle contractility per se are 
responsible for the luminal reduction and maintenance of high vascular pressures. 
 
Griffith et al. (7) reported the results of an investigation of pulmonary arterial muscle 
contractility and pulmonary arterial wall mechanics that support Reid’s (24) suggestion. 
Specifically, no increase in contractility was found in PASM from rats exposed to hypoxia for 14 
days. In fact, although no change was found in the tension-velocity relationship, a decrease in the 
active stress-developing ability was actually found in the hypertensive muscle. However, 
increases in passive stiffness and wall thickness were found, supporting the idea that increases in 
wall thickness, and connective tissue in particular, contribute to hypoxia-induced pulmonary 
hypertension. Despite the fact that an increase in PASM contractility is not responsible for the 
maintenance of hypertension, the smooth muscle may still be the cell type primarily involved in 
the development and indirectly in the maintenance of hypoxia-induced pulmonary hypertension. 
Changes in smooth muscle cell function in response to hypoxia or high transmural pressure may 
be responsible for the vascular wall thickening and increased connective tissue. For instance, a 
smooth muscle phenotypic change from a contractile to a synthetic cell type could be responsible 
for the majority of structural changes in the vessel wall and maintenance of the high vascular 
resistance. A less contractile phenotype would be accompanied by either no change or a decrease 
in vascular smooth muscle reactivity. Such phenotypic changes are known to occur in other 
models of hypertrophic or hyperplastic vascular smooth muscle (1) and could explain the source 
of the increased connective tissue in the walls of the hypertensive vessels. 
 
The purpose of the present study was to determine whether chronic hypoxia-induced pulmonary 
hypertension alters the sensitivity and/or reactivity of the PASM to a variety of agonists, 
including high K+ and several physiological agonists {norepinephrine (NE), angiotensin II (ANG 
II), serotonin [5-hydroxytryptamine (5-HT)], and adenosine (Ado)}, and to determine whether 
myosin heavy chain (MHC) isoform shifts correlate with the decreased ability of PASM to 
develop active stress in hypoxia-induced pulmonary hypertension. 
 
METHODS 
 
Adult (10-wk-old) Sprague-Dawley rats weighing 300–324 g were made hypoxic by lowering 
the fraction of inspired O2 (10%). Rats were placed in polycarbonate chambers, and N2mixed 
with room air (Venturi system) was allowed to flow into the chambers at 1.5 l/min. The animals 
were made hypoxic by lowering the fraction of inspired O2 to 15% for 24 h and then to 10% for 
the remainder of the 14 days. O2 and CO2 tensions were measured with Beckman O2 (model C-2) 
and CO2 (model LB-1) analyzers. O2 tension was monitored continuously with a Beckman OM-
15 O2 meter. PO2 was kept in the range of 75–80 Torr, and PCO2 was kept in the range of 0.3–
0.5 Torr. The chambers were opened every other day for feeding and cleaning to prevent 
ammonia buildup. Control animals were maintained under similar conditions but were allowed to 
breathe room air. 
 
After the 14-day hypoxic-exposure period, the rats were given an intraperitoneal injection of 
pentobarbital sodium (50 mg/kg body weight) and exsanguinated by section of the abdominal 
aorta. After the rats were anesthetized, blood samples for hematocrit determination were 
collected by insertion of a heparinized capillary tube into the area of the nasal canthus. Right 
ventricular pressure (PRV), an index of pulmonary arterial pressure, was measured in the rats after 
2 wk of chronic hypoxia and in age-matched control animals. To measure PRV, a polyethylene 
catheter (inner diameter 23 μm, outer diameter 38 μm) was introduced into the right jugular vein 
and manipulated into the right ventricle. Pressure traces were displayed on a Hewlett-Packard 
patient monitor (model 78353B) that provided digital presentation of systolic, diastolic, and 
mean pressures. The heart and lungs were removed, and the hearts were dissected free of all 
atrial tissue. The ratio of the right ventricle to the left ventricle plus septum weights was 
determined and used as an index of the relative degree of right heart hypertrophy. 
 
The lungs were placed in cold (4°C) Earle’s balanced salt solution (EBSS; 2.4 mM CaCl2, 0.8 
mM MgSO4, 5.4 mM KCl, 116.4 mM NaCl, 0.9 mM Na2HPO4, 5.5 mM d-glucose, 26.2 mM 
NaHCO3 and 0.03 mM phenol red sodium). The two main branches of the pulmonary artery 
were excised and cleaned of all visible parenchyma and connective tissue under a dissecting 
microcope. 
 
Some pulmonary arterial branches were prepared for morphometrics. In these cases, the 
pulmonary artery and its two major branches were isolated as described above except that the 
dissection was performed in Ca2+-free, EGTA-containing Krebs-Henseleit buffer (to ensure that 
the smooth muscle was fully relaxed). Under the dissecting microscope, each branch was cut into 
two ring segments such that four ring segments were obtained from each rat. The arteries were 
held on end and kept patent with surgical steel posts while they were completely immersed in 
fixative (2.5% glutaraldehyde and 1.5% paraformaldehyde in 0.1 M cacodylate buffer at 4°C) for 
2–4 h. Vessel segments were then postfixed in osmium tetroxide, dehydrated with alcohol, and 
embedded in Polybed 812. One-micrometer-thick sections were stained with toluidine blue. 
 
Photographs were taken of each arterial segment through the ×2.5 objective of a Zeiss Ultraphot 
microscope. This magnification allowed visualization of the entire vessel cross section in one 
visual field. These whole section micrographs (final magnification ×45) were utilized to measure 
arterial cross-sectional area (CSA) and luminal diameter. All other light micrographs were taken 
through the ×10 objective, resulting in visualization of only a segment of the vessel wall at a 
time. These micrographs (final magnification ×208) were then arranged in a collage to recreate 
the entire vessel cross section and were used to measure wall thickness, medial thickness, 
adventitial thickness, and number of smooth muscle cell layers. 
 
The ×45 micrographs were placed on a digitizing pad, and the inner and outer perimeters of each 
arterial wall were traced. With the use of planimetery software (SIGMASCAN, Jandel 
Scientific), two CSAs were calculated based on the inner and outer perimeters. The CSA of the 
vessel wall was then calculated by subtracting the inner CSA (i.e., lumen) from the outer CSA. A 
similar method was used to calculate the CSA of the medial layer. 
 
The ×208 micrographs were arranged as a collage to reconstruct the images of the transverse 
arterial cross sections. These collages were analyzed with a drafter’s T square to mark the vessel 
wall at points separated from each other by 90° angles. The T square was then rotated 45°, and 
four additional points of intersection were marked. At each of these eight points, the following 
measurements were made: total wall thickness, adventitial thickness, and number of smooth 
muscle cell layers. This process resulted in eight different independent measurements of each of 
these parameters for each vessel cross section. The eight measurements of each parameter were 
averaged for each section. Then the results, in mean values for each of the four sections of the 
same artery, were averaged together to give the mean wall thickness, medial thickness, 
adventitial thickness, and number of smooth muscle layers for each rat. The mean medial and 
adventitial thicknesses are expressed as percentages of the mean total wall thickness for each 
artery. Wall-to-lumen ratios were calculated from the wall thickness at each point divided by the 
mean luminal radius of the same section. Mean values from all the hypertensive arterial 
segments were then compared with those from control preparations. 
 
For the reactivity studies, main pulmonary arterial rings ranging from 1.5 to 2.0 mm in diameter 
and from 2.5 to 3.5 mm in length were gently threaded onto horizontally oriented, fixed-position 
surgical steel rods (300 μm in diameter, 5 mm in length) located in the lower third of 20-ml 
volume glass muscle baths. Once anchored to this wire, a second wire of the same dimensions 
but suspended from a force transducer (Grass Instruments, Quincy, MA) that was connected to a 
chart recorder (Gould) was introduced into each lumen above the first wire. Each muscle bath 
contained 10 ml of EBSS aerated with 95% O2-5% CO2. The outer jacket of each muscle bath 
was connected to a circulating water bath maintained at 37°C. 
 
In experiments in which ring segments denuded of endothelium were required, the endothelium 
was mechanically removed by threading the vessel onto a lightly sanded surgical steel rod and 
gently rotating the vessel twice in each direction. The integrity of the endothelium was tested by 
applying ACh (5 × 10−6 M) to NE-contracted arterial rings. Relaxation in response to ACh 
indicated insufficient removal of the endothelium, and data from such arterial rings were not 
used. In those experiments in which tachyphylaxis was a concern, this test of endothelial 
integrity was performed after washout of the last test drug used in the experiment. 
 
Once mounted, the arterial rings were equilibrated for 1 h at a resting tension ranging from 5.5 to 
8.0 mN. The optimal resting tension for maximal active tension development (Po) was previously 
determined to be 7.0 ± 0.8 mN for normal rat pulmonary arterial segments (25). Because the rats 
used for that previous study were much older (400–500 g), this same optimal resting tension was 
verified in normal rat pulmonary arterial segments from rats of the same age (300–325 g) as 
those used for all experiments described in this study. In addition, a rather extensive preliminary 
study of the active versus resting tension relationship in hypoxia-induced hypertensve rat arterial 
rings was carried out. The hypertensive muscle has a broader resting versus active tension curve 
plateau region compared with the control muscle. Changing resting tension in the 7- to 16-mN 
range had no significant effect on active tension production in the hypertensive preparations. 
These findings are similar to those reported by Griffith et al. (7). Therefore, an optimal resting 
tension value of 7.0 mN was used as the baseline tension for all experiments unless otherwise 
specified. Equilibration was followed by a maximal contraction with 80 mM KCl. The peak 
tension developed (in mN) was normalized to the CSA of the tissue (in mN/mm2). 
 
At the end of the pharmacological experiments, the length and width (diameter) of each vessel 
segment were measured. The vessel segments were then blotted, and the wet weight was 
obtained. Because the density of the tissue is close to one (1 mg/1 mm3), the weight of the tissue 
in milligrams is an estimate of the volume of tissue in cubic millimeters (i.e., density = 
mass/volume). The volume divided by the width of the muscle is then approximately equal to the 
CSA across which tension is developed (17). Po was determined for each vessel segment used in 
the pharmacological experiments and was defined as the maximum tension developed in 
response to supramaximal stimulation with 80 mM KCl. As the amount of muscle increases with 
thicker or longer ring segments, the absolute tension developed is also greater. Therefore, 
Po must be normalized to CSA for comparative purposes: Po/CSA = tension (in mN) developed 
in response to 80 mM KCl/[volume (in mm3)/width (in mm)]. 
 
The high-K+ solution used to obtain Po was subsequently washed out, and the muscle was 
allowed to relax completely. Each ring was then exposed to an agonist (5-HT, NE, ANG II, or 
Ado) with different randomly applied or cumulative doses (depending on the agonist). Example 
tension versus time tracings are shown in Fig.1. The magnitude of each response was normalized 
by expressing it as a percentage of the response to 80 mM KCl (%Po). 
 
 
Fig. 1. Tension vs. time tracings. An 80 mM KCl control contraction was followed by washout. Then a 
norepinephrine (NE;A)-, serotonin [5-hydroxytryptamine (5-HT)B]-, or angiotensin II (ANG II;C)-induced 
contraction was allowed to peak, and bath was flushed again. After complete relaxation, a higher dose of NE, 5-HT, 
or ANG II was introduced into the bath, resulting in a greater contractile response. Once the contractile response had 
reached a peak, vessel bath was again washed out, and relaxation was achieved. Tension produced in response to 
several different doses of NE, 5-HT, and ANG II was measured from this type of data, and complete dose-response 
curves were generated. Nos. in parentheses, dose. 
 
Each agonist solution was prepared as a high-concentration “stock” solution, divided into 1- to 2-
ml aliquots, and then frozen at −70°C. Serial dilutions of each stock solution were made on the 
day of the experiment, providing a series of agonist solutions that covered a range of several 
orders of magnitude (i.e., 10−10 to 10−3 M). For agonists that showed no tachyphylaxis (NE and 
Ado), it was possible to give additive doses to a given vessel without washing between doses. 
Serial-dilution solutions were added to the smooth muscle baths in small aliquots such that after 
each dose was added, the final concentration of the agonist was 10 times higher than the previous 
dose. For the other agonists (5-HT and ANG II), a single dose-response protocol (i.e., washing 
between doses) was utilized to ensure that tachyphylaxis of the muscle did not cause error in the 
dose-response curves generated. 
 
NE stock solution was made by dissolving 42.25 g of NE HCl (mol wt 205.6; Arterenol, Sigma) 
in 50 ml of sterile 0.9% NaCl. One hour after washout of the high-K+ solution, when tension 
reached a steady baseline, aliquots of this solution were added to the tissue bath in the following 
order of cumulative final doses: 10−10, 10−9, 10−8, 10−7, 10−6, 10−5, and 5 × 10−5 M. 
 
ANG II stock solution was made by dissolving 5 mg of ANG II (human synthetic form acetate 
salt, mol wt 1,046.3; Sigma) in 5 ml of sterile H2O. One hour after washout of the high-
K+solution, when tension reached a steady baseline, a single dose of ANG II was added to each 
bath. Because ANG II was one of the agonists that resulted in tachyphylaxis, a cumulative dose-
response protocol was not used. For the single dose-response experiments, aliquots of ANG II 
were added to the tissue bath to provide one of the following final concentrations of ANG II for 
each arterial ring: 10−6, 10−7, 2 × 10−8, 10−9, 10−10, and 10−11 M. 
 
5-HT stock solution was made by dissolving 0.1937 g of 5-HT (creatinine sulfate complex, mol 
wt 387.4; Sigma) in 3 ml of sterile H2O + 1 ml of EBSS. Then 0.100 ml of 5 N NaOH was added 
to bring the solution to a pH close to 7.4 (i.e., within the pH range of the phenol red sodium 
indicator that is a component of EBSS). One hour after washout of the high-K+solution, when 
tension reached a steady baseline, aliquots of these solutions were added to the tissue bath to 
create one of the following final concentrations of 5-HT in the tissue bath: 10−7, 10−6, 10−5, 2 × 
10−5, 10−4, or 10−3 M. 
 
Ado stock solution was made by dissolving 116.3 mg of Ado (hemisulfate form, mol wt 316.3; 
Sigma) in 10 ml of sterile H2O. One hour after washout of the high-K+ solution, when tension 
reached a steady baseline, vessels were precontracted with 10−5 M NE. As soon as the response 
to NE reached a plateau, aliquots of the Ado solution were added to the tissue bath in a 
sequential manner to reach cumulative concentrations of Ado as follows: 10−8, 10−7, 10−6, 10−4, 
and 10−3 M. 
 
KCl stock solution was made by dissolving 18.64 g of KCl (mol wt 58.44; Sigma) in 100 ml of 
sterile H2O and was stored at 4°C until used. For the initial maximal contraction in each 
pharmacological experiment, 320 μl of the KCl solution were added to each bath to give a final 
concentration of 80 mM KCl, previously shown to be more than sufficient to ensure a maximum 
isometric contraction (25). 
 
To determine whether hypoxia-induced pulmonary hypertension or removal of the endothelium 
resulted in changes in PASM reactivity or sensitivity to various physiological agents, dose-
response curves of the vasoconstrictors NE, ANG II, and 5-HT and to the vasodilator Ado were 
generated and compared. 
 
In other experiments, the main pulmonary arterial rings were prepared for MHC isoform and 
actin quantification. The main pulmonary arteries were dissected as described for the isometric 
tension studies. Due to the small absolute amount of muscle in rat pulmonary arteries, the two 
main branches and the trunk were used, and the muscle tissue of pulmonary arteries from four to 
five rats was combined for each sample. The arterial tissue was frozen in liquid N2, pulverized, 
acetone dried, desiccated under a low vacuum, and then stored at −70°C until used. For each 
experiment, 0.6 mg of each sample was dissolved in 100 μl of SDS-gel dissociation medium. 
The mixture was heated at 100°C for 30 min and centrifuged, and the supernatant was then 
applied to 5% acrylamide-0.75%N,N′-methylene-bis-acrylamide (BIS; 1.50% BIS for actin) gels 
with the buffer system of Porzio and Pearson (23). The samples were subjected to 
electrophoresis along with heavy-molecular-weight and BSA standards at 300 V and constant 
voltage at 10°C for ∼2–3 h for separation of actin and myosin and for 5 h for MHC isoform 
separation. After electrophoresis, the gels were stained with Coomassie blue, and myosin content 
was determined by quantitative densitometric scanning. 
 
Student’s t-test was used when comparing any two mean values for the hypertensive and control 
data. All results are expressed as mean values ± SE, andP < 0.05 is indicative of mean values 
that are significantly different from one another. Differences between any two cumulative dose-
response curves were demonstrated with a multiple (repeated)-measures ANOVA. For dose-
response curves obtained from individual (rather than cumulative) dose-response experiments, a 
two-way ANOVA for independent measures was utilized. To compare any two mean values at a 
given dose, Student’st-test was used. Myosin isoform ratios were compared with one-way 
ANOVA followed by the Newman-Keuls test. 
 
RESULTS 
 
The mean hematocrit for hypoxic rats (57.0 ± 1.0%; n = 9) is significantly greater than that of 
age-matched control rats (42.0 ± 1.5%; n = 13; P < 10−5). The right ventricle-to-left ventricle 
plus septum weight ratio for hypoxic rats (n = 24) is also significantly greater than that for 
control rats (0.40 ± 0.01 and 0.25 ± 0.01, respectively; n = 18; P < 10−6). The mean hypoxic rat 
(n = 4) PRV of 16.0 ± 0.7 mmHg is significantly higher than the mean control rat (n = 6) PRV of 
9.5 ± 0.3 mmHg (P < 0.00005). 
 
Both hypertensive (n = 4) and control (n = 4) pulmonary arteries demonstrated a loose outer 
adventitial connective tissue layer and inner organized smooth muscle layers. But only the 
hypertensive arteries had a poorly organized layer of cells between the inner organized smooth 
muscle layers and the outer connective tissue layer. Enlarged views of histological sections 
(×208) of arteries are shown in Fig. 2. The increase in the number of smooth muscle cell layers 
and the presence of an amorphous layer with either nonmuscle or migrated smooth muscle cells 
in the hypertensive arteries are evident in these micrographs. Figure2Bshows palisading nuclei 
within the inner, more organized smooth muscle cell layers, suggesting that the smooth muscle 
cells were cut in cross section and lie parallel to the longitudinal axis of the vessels. The 
amorphous layer does not show such palisading nuclei, and the direction in which these cells are 
oriented could not be determined. None of the sections demonstrates any clear changes in the 
intima associated with hypoxia-induced hypertension. There was no evidence of intimal 
proliferation, and no atherosclerotic changes were seen with light microscopy. 
 
 
Fig. 2. Micrographs of main pulmonary arterial cross sections stained with toludine blue. Hypertensive arteries 
(B and C) have much thicker walls, increased number of smooth muscle layers and an additional amorphous layer of 
cells compared with control artery (A). Also note presence of palisading nuclei in organized smooth muscle layers, 
indicating that cells are parallel to one another and to longitudinal axis of vessel wall (B) but are lacking in the 
amorphous layer (C) of hypertensive arterial section, indicative of disorganization, possibly due to hyperplasia 
rather than to hypertrophy. Final magnification, ×208. 
 
The mean CSA for control and hypertensive pulmonary arteries and other morphometric values 
determined from light micrographs are shown in Table 1. The mean CSA of hypertensive 
pulmonary arteries measured from light micrographs is approximately double the mean CSA of 
control pulmonary arteries. The mean hypertensive pulmonary arterial wall thickness and 
adventitial and medial thicknesses are all significantly greater than the mean control thicknesses. 
Even when the medial thickness of the hypertensive pulmonary arteries was measured without 
including the outer amorphous muscle layer (media − outer layer), the mean is significantly 
greater than that of the control arteries. The mean number of smooth muscle cell layers is 
increased, whereas the thickness of the cell layers, excluding the outer amorphous layer, is 
unchanged in the hypertensive pulmonary arteries relative to the control arteries. The mean 
luminal radius is also not different between the hypertensive and control arteries. Although there 
is a significant increase in the mean adventitial thickness in the hypertensive pulmonary arteries, 
the proportion (in percent) of the wall that is composed of adventitia in the hypertensive arteries 
is not significantly different from that in the control arteries. Similarly, the proportion of the 
medial thickness relative to the wall thickness is unchanged in the hypertensive arteries relative 
to that in the control arteries. Although the radius of the lumen is not different, the wall thickness 
is increased in the hypertensive pulmonary arteries as reported above, and, therefore, the wall-to-
lumen ratio in the hypertensive arteries is significantly greater than that in the control arteries. 
 
Table 1. Rat pulmonary artery morphometrics 
Parameter Hypertensive Control 
Wall thickness, mm 0.152 ± 0.006‡ 0.076 ± 0.005 
Media, mm 0.105 ± 0.003‡ 0.047 ± 0.003 
 % Wall 69.2 ± 3.3* 61.8 ± 2.1 
Media − OL, mm 0.059 ± 0.001* 0.047 ± 0.003 
 % Wall 39.1 ± 0.8‡ 61.8 ± 2.1 
Adventitia, mm 0.047 ± 0.006* 0.029 ± 0.003 
 % Wall 30.8 ± 3.3 38.3 ± 2.0 
Luminal radius, mm 0.755 ± 0.009 0.763 ± 0.019 
Wall-to-lumen ratio, % 20.1 ± 0.7‡ 9.9 ± 0.7 
No. of smooth muscle layers 5.2 ± 0.4† 3.1 ± 0.1 
Individual smooth muscle cell layer thickness, mm 0.014 ± 0.001 0.016 ± 0.001 
Wall cross-sectional area, mm2 0.92 ± 0.11‡ 0.44 ± 0.03 
Media cross-sectional area, mm2 0.49 ± 0.03‡ 0.27 ± 0.02 
Values are means ± SE; n = 4 arteries/group. OL, outer amorphous layer of smooth muscle cells. Significantly 
different from control arteries: *P < 0.05; †P < 0.005; ‡P < 0.001. 
 
Control vessels with and without endothelium responded to doses of NE ≥ 10−6 M with sustained 
contractions for >1 h. Hypertensive vessels (n = 49) required a dose of ≥10−5 M NE to evoke a 
sustained response. The NE dose-response curves for pulmonary arterial preparations with and 
without endothelium are shown in Fig.3A. There is a general upward shift in the dose-response 
curve for pulmonary arteries without endothelium (F = 23.987; P< 0.001). The NE dose-
response curves for hypertensive and control pulmonary arteries obtained from single-dose 
experiments are shown in Fig.3B. There is a general downward shift in the hypertensive dose-
response curve relative to the control curve (F = 116.878;P < 0.001). The mean maximum 
response of the hypertensive arteries (95.9 ± 8.4%Po;n = 9) is significantly lower than the mean 
control response to the same dose (133 ± 0.2%Po;n = 6;P< 0.05). The NE dose-response curves 
for control pulmonary arteries (with endothelium) exposed to the same range of NE doses as 
those used above but under acute normoxic and hypoxic conditions are shown in Fig.3C. The 
PO2 measured in the hypoxic tissue baths was 28.3 ± 1.2 Torr (n = 4 arteries). Acute in vitro 
hypoxia resulted in a general downward shift in the NE dose-response curve relative to the 
control curve (F= 140.839; P < 0.001). 
 
 
Fig. 3. NE dose-response curves for endothelium-denuded pulmonary arterial muscle (A), hypoxia-induced 
pulmonary hypertensive (PHT) pulmonary arterial muscle (B), and control pulmonary arterial muscle under in vitro 
normoxic and acute hypoxic conditions (C). %Po, maximal active tension development normalized by expression as 
percentage of response to 80 mM KCl; [NE], NE concentration. Nos. in parentheses, no. of arteries. PHT curve was 
shifted below control curve, indicating decreased reactivity of PHT arterial muscle to NE. Curve for muscle under 
hypoxic conditions was shifted well below control curve. * P < 0.05. 
 
 
Fig. 4. ANG II dose-response curves for endothelium-denuded (A) and PHT (B) rat pulmonary arterial muscle 
compared with control muscle. [ANG II], ANG II concentration. Nos. in parentheses, no. of arteries. Endothelium-
denuded muscle was more reactive than endothelium-intact muscle. PHT curve was shifted well below control 
curve, indicating decreased reactivity of PHT arterial muscle to ANG II. *P < 0.05. 
 
The ANG II dose-response curves for pulmonary arteries with and without endothelium are 
shown in Fig.4A. There is a general upward shift in the dose-response curve for denuded vessels 
compared with control arteries (F = 23.987; P < 0.001). The mean maximum response of the 
arteries without endothelium (70.2 ± 6.8%Po; n = 10) occurred at 10−8 M ANG II and is 
significantly greater than that of control arteries with endothelium (29.6 ± 8.1%Po; n = 6; P < 
0.05) at the same dose. The ANG II dose-response curves for hypertensive and control 
pulmonary arteries (both with endothelium) are shown in Fig.4B. There is a general downward 
shift in the hypertensive dose-response curve relative to the control curve, as in the case of NE 
(F = 48.024; P < 0.001). The mean maximum response of the hypertensive arteries to ANG II 
(17.3 ± 3.0%Po; n = 8) is significantly different from that of the control arteries at the same dose 
(36.2 ± 9.3%Po; n = 5; P < 0.05). 
 
The mean dose-response curves for 5-HT in pulmonary arteries with and without endothelium 
are shown in Fig.5A. There is a general upward shift in the dose-response curve for vessels 
without endothelium (F = 47.34; P < 0.001). The mean maximum response to 5-HT is 95.6 ± 
2.4%Po in the segments without endothelium (n = 3), which is significantly greater than the mean 
maximum response for control segments (46.3 ± 5.8%Po;n = 6;P < 0.05). The 5-HT dose-
response curves for hypertensive and control pulmonary arteries (both with endothelium) are 
shown in Fig. 5B. There is no significant difference between the hypertensive and control dose-
response curves for 5-HT (F = 3.33; P > 0.05). The mean maximum response of the hypertensive 
arteries to 5-HT (61.4 ± 8.9%Po; n = 3) is not significantly different from the mean control 
response at the same dose (53.0 ± 9.4%Po; n = 6; P > 0.05). 
 
 
Fig. 5. 5-HT dose-response curves for endothelium-denuded (A) and PHT (B) rat pulmonary arterial muscle 
compared with control muscle. [5-HT], 5-HT concentration. Nos. in parentheses, no. of arteries. Disruption of 
endothelium results in increased reactivity to 5-HT as for NE and ANG II. Control and PHT curves are not 
different, P > 0.05; *P < 0.001. 
 
No response to Ado could be elicited in vessels unless they were actively precontracted. Arterial 
segments (n = 4) at resting tension did not respond to any dose of Ado. NE was chosen as the 
agonist for precontracting the vessels because it provided a reproducible response to a given dose 
and a relatively sustained plateau (i.e., >1 h for doses > 10−6 M; n = 21). Doses of 10−8 to 10−3 M 
Ado did not elicit any response in the resting vessels but resulted in either contraction or 
relaxation of NE-precontracted pulmonary arteries depending on the Ado concentration as 
previously reported (26). At low doses of Ado, the response varied from slight relaxation to 
slight contraction. At higher doses of Ado, only relaxation occurred. The response to a given 
dose of Ado was usually maintained regardless of whether it resulted in an increase or decrease 
in tension. Only control vessels displayed contraction in response to low doses of Ado. 
 
 
Fig. 6. Adenosine (Ado) dose-response curves for pulmonary arterial segments from control and hypoxia-induced 
PHT rats. Ado responses are expressed as percent of response to 10−5 M NE. [Ado], Ado concentration. Nos. in 
parentheses, no. of arteries. The 2 curves are similar except for small contractile response of control pulmonary 
arterial smooth muscle at low doses (10−6 and 10−5 M) of Ado and decreased relaxation response of PHT muscle at a 
higher dose (10−3 M) of Ado. * P < 0.05. 
 
 
Fig. 7. KCl dose-response curves for rat pulmonary arterial smooth muscle. [KCl], KCl concentration. n, No. of 
arteries. Comparison of mean control and hypoxia-induced PHT curves shows no difference, P > 0.05. However, 
this method of tension normalization (i.e., %Po) does not take changes in wall content of muscle or in muscle 
function into consideration. 
 
The effect of endothelium removal on the response of pulmonary arterial muscle to Ado has been 
previously reported (26). Briefly, there was a slight contractile response at 10−6 M Ado in vessels 
with intact endothelium (4.1 ± 2.2%Po;n = 10;P < 0.05). No contractile response to Ado was 
observed for rat pulmonary arteries without endothelium. Vessels denuded of endothelium 
responded with relaxation over the range of 10−7 to 10−3 M Ado. Higher doses of Ado (≥10−4 M) 
resulted in relaxation of the same magnitude in both vessels with intact endothelium and vessels 
without endothelium. The mean Ado dose-response curves for hypertensive and control 
pulmonary arteries are shown in Fig. 6. Unlike control arteries, no contractile response to Ado 
was observed for hypertensive rat pulmonary arteries. The hypertensive pulmonary arteries 
responded to Ado with relaxation over the dose range of 10−8 to 10−3 M. At the highest dose of 
Ado (10−3 M), the hypertensive arteries did not demonstrate as much relaxation (−42.2 ± 
4.9%; n = 5) as the control arteries. 
 
 
Fig. 8. Comparison of cross-sectional area (CSA;A, C, and E) and Po normalized to CSA (B, D, and F) for control 
pulmonary arterial segments with segments from hypoxia-induced PHT rats using 2 different methods of 
determination of CSA. n, No. of arteries. Total calculated CSA of hypertensive pulmonary arterial segments is 
greater than that of control segments (A). Po normalized to calculated CSA is less in hypertensive than in control 
pulmonary arterial muscle (B). These conclusions hold true when CSA is determined by morphometric analyses 
(C and D, respectively) and also when only vessel wall medial layer CSA is compared (E) and when Po is 
normalized to medial CSA rather than to total (i.e., whole wall) CSA (F). * P < 0.05 compared with respective 
control arteries. 
 
The KCl dose-response curves from hypertensive and control pulmonary arteries are shown in 
Fig. 7. Arterial ring segments were exposed to KCl doses in the range of 20–120 mM, and the 
active responses are expressed as a percentage of the maximal response to 80 mM KCl. This 
method of normalization of the responses allows for comparison of the mean dose-response 
curves to ensure that when the rats were made hypertensive, the sensitivity and relative 
responsiveness to KCl were not altered. The curves are almost superimposable, and there is no 
significant difference in the response at any dose of KCl (P > 0.05). Tension-generating ability 
was determined by comparing responses normalized to the amount of smooth muscle (i.e., CSA) 
as shown in Fig.8. The hypertensive pulmonary arterial muscle tension-generating ability is 
reduced compared with control preparations when normalized for the proportionate amount of 
muscle in the tissue CSA (P < 0.05). 
 
Analyses of densitometric scans of the 1.5% BIS-SDS-polyacrylamide gels showed that there 
was no difference in the amount of actin relative to the amount of total protein (i.e., peak 
areas/mg dry weight of total protein) in hypertensive compared with control myofibrillar protein 
(1,100 ± 120 and 988 ± 110 mm2/mg protein, respectively). Similarly, there is no difference in 
the actin-to-myosin ratios of hypertensive PASM (2.19 ± 0.12) and the control PASM (1.90 ± 
0.14). Scans of the 0.75% BIS-SDS-polyacrylamide gels revealed four distinct myosin isoforms 
for both control and hypertensive pulmonary arterial muscles (20). The four MHCs have 
molecular masses of ∼204, 200, 196–198, and 190 kDa (MHC204, MHC200, MHC196, and 
MHC190, respectively). Other investigators have identified four isoforms in other smooth muscles 
(5) and the latter two isoforms in nonmuscle cells (16). The relative amounts of these various 
isoforms in hypertensive and control pulmonary arterial muscles are compared in Table 2. The 
hypertensive and control ratios of MHC200 to MHC204 are not significantly different (P > 0.05). 
However, the MHC190+196/MHC200+204ratio is higher in the hypertensive than in the control 
pulmonary arterial muscle (P < 0.05). 
 
Table 2. Comparison of pulmonary arterial MHC isoform ratios 
 Hypertensive Control 
MHC200/MHC204 0.987 ± 0.417 1.134 ± 0.229 
 (n = 4) (n = 8) 
MHC196+190/MHC204+200 0.339 ± 0.041† 0.136 ± 0.068 
 (n = 4) (n = 4) 
MHC196/MHC204+200 0.256 ± 0.032* 0.178 ± 0.032 
 (n = 8) (n = 8) 
Values are means ± SE; n, no. of electrophoresis runs. Value from each run is actually a mean value of 4 lanes (4 
samples). And, in turn, each sample represents protein from pulmonary arteries of 5 rats. Therefore, 
each n represents data from 20 or more rats. MHC, myosin heavy chain. Subscript nos., molecular mass (in kDa) of 
MHC isoforms. Significantly different from control values: *P< 0.02; †P < 0.00002. 
 
DISCUSSION 
 
Results of this study show that after 14 days of hypoxia there is an increase in the adventitial and 
medial thicknesses but no change in the percent contribution of the media to the wall thickness in 
rat pulmonary arterial walls. Similar results have been previously reported (7). Reid (24) found 
approximately a doubling in thickness of the arterial smooth muscle in all the muscular arteries 
as well as an extension of muscle into previously nonmuscular peripheral arteries. This doubling 
of muscle means a greater absolute amount of muscle. An increase in the mean number of layers 
of smooth muscle from 3.1 in control arteries to 5.2 in hypertensive pulmonary arteries, with no 
increase in the thickness of each muscle layer, as shown in this study, suggests smooth muscle 
hyperplasia has occurred at this stage (14 days of hypoxia). The luminal radius is not altered in 
the hypertensive arteries, but the adventitial layer is almost double that observed for control 
arteries. In addition, there is an increase in the number of cells in the adventitial layer close to the 
media. These cells are not organized into a layer with uniform thickness like the medial layers 
nor are the elastic fibers organized into a continuous concentric band, suggesting that either 
hyperplasia of smooth muscle is not occurring on the luminal side of the vessel but rather on the 
adventitial side, at least in the large hilar arteries utilized in this study, or nonmuscle cells such as 
fibroblasts are proliferating in the adventitia of hypertensive arteries. 
 
A response to a given agonist depends on the number of receptors, affinity of the receptors, 
intracellular coupling mechanisms, and, ultimately, the number of tension-generating sites (i.e., 
actin and myosin interactions) in vascular smooth muscle. Normalizing the Po produced to the 
tissue CSA provides an index of the number of tension-generating sites per unit of wall CSA. 
However, this method of normalization does not take into consideration changes in vessel wall 
composition. A method of normalization that allows for comparisons of changes in reactivity to 
the specific agonist regardless of changes in wall structure is to express the response as a 
proportion of a maximal contraction for the preparation in response to membrane depolarization 
(%Po). Normalization of agonist responses to the magnitude of the maximal KCl response allows 
for determination of whether differences in the active responses to various agonists are specific 
to a particular agonist or are due to a general alteration in contractility. 
 
The pulmonary arterial segments from both control and hypertensive rats responded to the same 
range of NE doses (i.e., 10−10 to 10−4 M), with a peak response at 10−5 to 10−4 M, in agreement 
with that reported by other investigators (13). The general upward shift in the NE dose-response 
curve for endothelium-denuded vessels is likely simply due to a decrease in endothelium-derived 
relaxing factor because there is increased reactivity of the PASM to all contractile agonists 
(ANG II, NE, and 5-HT) investigated when the endothelium is rendered nonfunctional. The fact 
that sustained tension in the hypertensive vessels required a higher dose (≥10−5 M) than in 
control vessels suggests that there may be a change in receptor function or a coupling when the 
smooth muscle is made chronically hypoxic. β-Adrenergic receptors could play a greater role in 
hypertensive compared with control rats, and, therefore, a higher dose of NE would be required 
to overcome the relaxation effects of the β-receptors. This idea is supported by the fact that, after 
5 days to 2 wk of hypoxia, pulmonary arteries show less vasoconstriction in response to NE 
(12, 19, 22) and that the vasoconstriction is augmented with β-receptor blockade (12, 22). A 
decrease in ability to develop tension relative to the CSA could be due to the loss of contractile 
function in some of the smooth muscle cells and/or a disproportionate increase in connective 
tissue. However, the NE responses were normalized to Po, and, therefore, the decrease in the 
absolute ability of the smooth muscle to develop tension cannot account for the decrease in NE 
reactivity observed. Therefore, a change in NE-receptor function, such as receptor 
downregulation, must have occurred with the development of pulmonary hypertension. A 
decreased vasoconstriction (decreased vascular resistance) in response to NE has also been 
reported in isolated lungs from chronically hypoxic rats (22). 
 
A decrease in reactivity to NE was also observed in isolated pulmonary arteries from control rats 
that were exposed to acute hypoxia (i.e., in vitro hypoxia). This is possibly due to a generalized 
decrease in reactivity in response to all agonists during acute hypoxia because Lloyd (11) 
showed that hypoxic media decreased the response to electrical stimulation, 5-HT, NE, ANG, 
K+, and ACh without altering resting tension. Harabin et al. (8) found a decrease in reactivity to 
PGF2α and ANG II in isolated perfused pig lungs exposed to an inspired PO2 < 30 Torr. But these 
investigators found no change in reactivity to KCl and therefore concluded that it was unlikely 
that the supply of ATP available for contraction was limiting. A decrease in PO2 results in 
membrane depolarization and an increased voltage-dependent permeability to Ca2+ (6). It is 
possible that, because the membrane is already partly depolarized by hypoxia, the amount of 
further depolarization due to other stimuli is limited, and hence the magnitude of the response to 
stimuli other than hypoxia is reduced. Another hypothesis for the decreased reactivity to NE is 
that hypoxia may result in the release of mediators that bind nonspecifically to and result in 
“heterologous” desensitization of the adrenergic receptors (10). Or such mediators might cause 
downregulation of the adrenergic receptors. Last, endothelium-derived factors such as 
endothelium-derived relaxing factor (NO) or endothelium-derived hyperpolarizing factor, 
reactive oxygen species, or NO from smooth muscle might be released in greater quantity after 
chronic hypoxia or a return to normoxia, thus compromising force development in response to 
high K+or contractile agonists. The mechanisms for the decrease in responsiveness to NE during 
acute hypoxia and chronic hypoxia may or may not be the same. Important to note is that the 
literature is not in complete agreement about the effect of chronic hypoxia-induced pulmonary 
hypertension on NE reactivity, but this is likely due to differences in methodology. For example, 
McMurtry et al. (14) found an increase in response to NE in isolated perfused lungs from rats 
with chronic hypoxia-induced pulmonary hypertension. However, their data were not normalized 
and reflected the responses of the entire pulmonary circulation rather than those of isolated 
arterial muscle. 
 
From the pilot studies with ANG II, it appeared that the peak response occurred at an ANG II 
dose of 10−7 M, and higher doses actually resulted in lower responses. Therefore, the range of 
doses was set at 10−10 to 10−6 M to ensure that a supramaximal dose was included for the purpose 
of demonstrating a maximum peak. However, the great variability in the magnitude for the 
responses of ANG II resulted in mean curves that do not have a clear maximum over the range of 
doses tested. When several higher doses were tested, the response was always submaximal. 
Similar dose ranges have been used by other investigators (13). It is worth noting that McMurtry 
et al. (13) did not use a supramaximal dose for ANG II, whereas Chand and Altura (2) did show 
a supramaximal response to ANG II at 10−7 M. 
 
The ANG II dose-response curve of the hypertensive arteries is significantly shifted downward 
compared with the control curve, demonstrating a decrease in reactivity to ANG II in the arteries 
from rats exposed to chronic hypoxia. McMurtry et al. (13) also showed a decreased response to 
ANG II in both isolated perfused lungs and isolated main pulmonary arterial segments after 
exposure to chronic hypoxia. The possible explanations for the decrease in reactivity may be 
similar to those for NE, including heterologous (i.e., nonspecific) desensitization or receptor 
downregulation. 
 
The 5-HT dose-response curve for the hypertensive PASM was not significantly different from 
that for the control PASM. 5-HT was the only agonist that did not lose its potency in eliciting a 
contraction as a result of chronic hypoxia. Downregulation of receptors with hypoxia may be 
receptor specific, or perhaps only certain intracellular coupling mechanisms are affected by 
chronic hypoxia. 
 
Previously, Roepke et al. (26) reported that the predominant effect of Ado in the pulmonary 
circulation is vasodilation. Results of the present study show that hypertensive pulmonary 
arterial rings also relax in response to Ado. However, the relaxation induced by high doses of 
Ado was not as great in the hypertensive rings as in either endothelium-denuded or -intact 
control PASM rings. The decreased ability to relax in response to Ado may be contributing to the 
pulmonary hypertension. 
 
Hypertensive rat pulmonary arteries show no difference in absolute maximum tension 
development (i.e., response to high K+) from control arteries. This is surprising at first glance 
because pulmonary hypertension is associated with hypertrophy of the smooth muscle. 
McMurtry et al. (13) demonstrated that the pressor response to KCl is diminished in both isolated 
perfused lungs and isolated main pulmonary arterial segments from rats with chronic hypoxia-
induced pulmonary hypertension. Because morphometric measurements in this study showed 
that there is an increase in CSA of the medial layer, it is best to normalize the KCl responses to 
the CSA. The finding that the CSA is doubled in the hypertensive vessels is supported by the fact 
that other investigators (7, 24) have shown a similar doubling of CSA. Results of this study show 
that the mean Po normalized in this manner (i.e., Po/CSA) is decreased in the hypertensive 
PASM. A decreased Po/media CSA may be explained by an increase in the proportion of 
noncontractile to contractile smooth muscle (i.e., a phenotypic change) and/or a disproportionate 
increase in connective tissue in the hypertensive arteries. 
 
Results of this study show the presence of four protein bands on SDS gels that closely 
correspond in molecular mass to those of myosin. The two densest bands (204 and 200 kDa) are 
the two forms of MHC (MHC200 and MHC204, respectively) consistently found in a variety of 
mammalian smooth muscles (17, 18, 27, 29). Although these two MHCs are present in most 
smooth muscle tissues, the ratio of the amount of MHC204 to MHC200 varies depending on the 
specific smooth muscle tissue type from which myosin is isolated (16,29) and the animal’s age 
(4, 15). Two other bands appear on the gels at the 190- and ∼196- to 198-kDa positions. 
Degradation experiments have ruled out the possibility that the 190-kDa protein is a degradation 
product of MHC204 and MHC200. Eddinger and Murphy (4) reported an MHC of 190 kDa that 
they isolated “most readily” from uterine tissue of the guinea pig and mouse, and it has also been 
isolated from aortic tissue from both of these species. These investigators claim that it has not 
been isolated from the rat, rabbit, or pig, although the rat pulmonary artery was not investigated. 
Another protein band that has a mobility intermediate between MHC200 and MHC190, at ∼196–
198 kDa, has been reported (9, 27, 28). The 190- and 196- to 198-kDa MHCs have been 
described as nonmuscle MHCs and have been labeled nonmuscle myosin. Although in this study 
no change in the MHC200/MHC204 ratio was found in the hypoxia-induced pulmonary 
hypertensive pulmonary arterial smooth muscle, an increase in the ratio of MHC190+196 to 
MHC200+204 in the hypertensive PASM did occur. Two clearly defined smooth muscle 
phenotypes have been reported: the contractile and the synthetic phenotypes (1). There is a 
relatively greater amount of nonmuscle myosin (i.e., MHC190 and MHC196) in tissues from young 
animals, and the ratio of nonmuscle to muscle (MHC204 and MHC200, respectively) myosin 
decreases with age (4, 15). An abundance of nonmuscle myosin may represent a less 
differentiated state of smooth muscle cells in the case of development or that more of the muscle 
is in the synthetic phenotype. On the other hand, expression of nonmuscle myosin could just as 
easily be due to an increase in the number of nonmuscle cells, a possibility that cannot be 
contradicted without definitive staining in situ. However, a definitive immunohistochemical stain 
distinguishing synthetic smooth muscle from nonmuscle cells such as fibroblasts has not yet 
been identified. 
 
In conclusion, the main findings of this investigation may be summarized as decreased reactivity, 
decreased tension production per unit of CSA of muscle despite hyperplasia, and an increase in 
the proportion of nonmuscle myosin to muscle myosin isoforms in the pulmonary arterial wall 
with pulmonary hypertension. The cause-and-effect relationship between these parameters 
remains to be established. 
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